NL-OMON46330撤回2 期
A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib (MSC2156119J) Combined with Gefitinib Versus Chemotherapy as Second-line Treatment in Subjects with MET Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance to Prior EGFR-Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy - EMR200095-006 Tepotinib with Gefitinib in Subjects with NSCLC (INSIGHT)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- Merck
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •a) Locally advanced or metastatic NSCLC other than predominantly squamous histology (confirmed by either histology or cytology);
- •b) Activating mutation of the EGFR receptor (documented, or as determined by the central laboratory);
- •c) Acquired resistance on first-line EGFR-TKI therapy including gefitinib, erlotinib, icotinib, or afatinib;
- •d) EGFR T790M status (as determined by the central laboratory, using a validated PCR test);
- •- T790M negative status for the randomized part
- •- T790M positive status for the single-arm cohort (mainland China sites only)
- •e) Availability of a fresh or archived tumor tissue (excluding fine needle aspiration and cytology samples) obtained between documentation of acquired resistance to EGFR-TKI therapy including gefitinib, erlotinib, icotinib, or afatinib and enrollment is mandatory;
- •f) MET+ status, as determined by the central laboratory, i.e. c-Met overexpression as determined by IHC (i.e., IHC 2+ or IHC 3+) and/or c-Met amplification and/or increased c-Met gene copy number (GCN), both determined by ISH;
- •g) ECOG PS of 0 or 1.
排除标准
- •Cancer Related
- •1.Symptomatic metastasis of brain and/or CNS, uncontrolled with antiepileptics and requiring steroids, unless treated and stable without steroids for at least 10 days within 4 weeks prior to the first dose of trial treatment;
- •2.Any unresolved toxicity more than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.0) Grade 2 from previous anticancer therapy;
- •3.Estimated life expectancy < 3 months;
- •4.Need for transfusion within 14 days prior to the first dose of trial treatment;
- •5.Prior chemotherapy, biological therapy, radiation therapy, or other investigational anticancer therapy (not including palliative radiotherapy at focal sites) within 21 days prior to the first dose of trial treatment.;1.Prior systemic anticancer treatment with eg. chemotherapy or any other agents excluding gefitinib, erlotinib, icotinib, and afatinib for advanced NSCLC (one course of chemotherapy regimen for [neo]adjuvant purpose, or one course of chemoradiation for Stage IIIa disease is allowed)
- •2.Prior treatment with other agents targeting the HGF/c-Met pathway;Laboratory Values and Organ Function
- •1.Inadequate hematological function:Hemoglobin < 8.5 g/dLNeutrophils < 1.5 × 109/LPlatelets < 100 × 109/L
- •2.Inadequate liver function:Total bilirubin > 1.5 × upper limit of normal (ULN)Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 3 × ULN;
- •For subjects with liver metastases:Total bilirubin > 1.5 × ULNAST/ALT > 5 × ULN
- •3.Known pre-existing interstitial lung disease
- •4.Inadequate renal function:
- •6.Renal impairment as evidenced by serum creatinine * 1.5 × ULN, or creatinine clearance (CrCl) < 60 mL/min calculated by the Cockcroft-Gault formula (24 hour CrCl might be requested by the investigator for confirmation, if calculated CrCl is < 60 mL/min. In such case, subjects with 24 hour CrCl < 60 mL/min should be excluded
- •5.Subjects who have ongoing medical history of acute pancreatitis and/or chronic pancreatitis, with concomitant elevated lipase and/or amylase, clinical symptoms, and/or imaging studies that are indicative of the diagnosis (subjects in mainland China only);General
- •1.Impaired cardiac function
- •Left ventricular ejection fraction (LVEF) < 45% defined by
- •echocardiography (a screening LVEF assessment without history of congestive heart failure [CHF] is not required)
- •Serious arrhythmia
- •Unstable angina pectoris
- •CHF New York Heart Association (NYHA) III and IV (Appendix E)
- •Myocardial infarction within the last 12 months prior to trial entry
- •Signs of pericardial effusion
- •2.Hypertension uncontrolled by standard therapies (not stabilized to <150/90 mmHg)
- •3.Contraindication to the administration of gefitinib
- •4.Medical history of liver fibrosis/cirrhosis
- •5.Past or current history of neoplasm other than NSCLC, except for curatively treated non melanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at least 5 years;
- •6.Medical history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product
- •7.Major surgery within 28 days prior to Day 1 of trial treatment
- •8.Known human immunodeficiency virus positivity
- •9.Substance abuse, active infection, or other acute or chronic medical or psychiatric condition or laborat
研究者
相似试验
进行中（未招募）
1 期
Tepotinib with Gefitinib in Subjects with Locally Advanced or Metastatic NSCLC (INSIGHT)ocally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)MedDRA version: 20.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001604-28-NLMerck KGaA156
进行中（未招募）
1 期
Tepotinib with Gefitinib in Subjects with Locally Advanced or Metastatic NSCLC (INSIGHT)ocally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)MedDRA version: 19.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001604-28-SKMerck KGaA192
进行中（未招募）
1 期
Tepotinib with Gefitinib in Subjects with Locally Advanced or Metastatic NSCLC (INSIGHT)ocally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)MedDRA version: 19.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001604-28-BGMerck KGaA192
进行中（未招募）
1 期
Tepotinib with Gefitinib in Subjects with Locally Advanced or MetastaticNSCLC (INSIGHT)ocally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001604-28-ITMERCK KGAA192
进行中（未招募）
1 期
Tepotinib with Gefitinib in Subjects with Locally Advanced or Metastatic NSCLC (INSIGHT)EUCTR2016-001604-28-ESMerck KGaA192